Absence of CD4(+) T cell help generates corrupt CD8(+) effector T cells in sarcoma-bearing Swiss mice treated with NLGP vaccine

Immunol Lett. 2016 Jul:175:31-9. doi: 10.1016/j.imlet.2016.05.004. Epub 2016 May 10.

Abstract

One of the prime objectives of cancer immunology and immunotherapy is to study the issues related to rescue and/or maintenance of the optimum effector CD8(+) T cell functions by minimizing tumor-induced negative factors. In this regard the influence of host intrinsic CD4(+) helper T cells towards generation and maintenance of CD8(+) effector T cells appears controversial in different experimental settings. Therefore, the present study was aimed to re-analyze the influence of CD4(+) helper T cells towards effector T cells during neem leaf glycoprotein (NLGP)-vaccine-mediated tumor growth restriction. CD4 depletion (mAb; Clone GK1.5) surprisingly resulted in significant increase in CD8(+) T cells in different immune organs from NLGP-treated sarcoma-bearing mice. However, such CD8 surge could not restrict the sarcoma growth in NLGP-treated CD4-depleted mice. Furthermore, CD4 depletion in early phase hinders CD8(+) T cell activation and terminal differentiation by targeting crucial transcription factor Runx3. CD4 depletion decreases accumulation of CD8α(+) dendritic cells within tumor draining lymph node, hampers antigen cross priming and CD86-CD28 interactions for optimum CD8(+) T cell functions. In order to search the mechanism of CD4(+) T cell help on NLGP-mediated CD8 effector functions, the role of CD4(+) helper T cell-derived IL-2 on optimization of CD8 functions was found using STAT5 signaling, but complete response requires physical contact of CD4(+) helper T cells with its CD8 counterpart. In conclusion, it was found that CD4(+) T cell help is not required to generate CD8(+) T cells but was found to be an integral phenomenon in maintenance of its anti-tumor functions even in NLGP-vaccine-mediated sarcoma growth restriction.

Keywords: CD4(+)/CD8(+) T cells; IL-2; Neem leaf glycoprotein; RunX3; Sarcoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / immunology*
  • Azadirachta / immunology
  • CD4 Antigens / metabolism
  • CD8 Antigens / metabolism
  • Cancer Vaccines / immunology*
  • Cell Growth Processes
  • Cell Line, Tumor
  • Cells, Cultured
  • Cytotoxicity, Immunologic
  • Dendritic Cells / immunology*
  • Female
  • Growth Inhibitors / immunology*
  • Interleukin-2 / metabolism
  • Lymphocyte Depletion
  • Mice
  • Neoplasms, Experimental
  • Sarcoma / immunology*
  • T-Lymphocytes, Cytotoxic / immunology*
  • T-Lymphocytes, Helper-Inducer / immunology*

Substances

  • Antineoplastic Agents
  • CD4 Antigens
  • CD8 Antigens
  • Cancer Vaccines
  • Growth Inhibitors
  • Interleukin-2